To provide a method for efficiently utilizing bacterial cells and unused raw materials for culture in the manufacture of fermentation products.

A method for manufacturing a fermentation product by culturing a microorganism, the method comprising steps (A) to (D): step (A) of culturing the microorganism with a first culture medium; step (B) of passing a culture solution containing cultured bacterial cells, raw materials for culture, and the fermentation product through an adsorption tower packed with an adsorbent capable of adsorbing the fermentation product to adsorb the fermentation product from the culture solution to the adsorbent, and then collecting an effluent containing the bacterial cells and the raw materials for culture flowing out from the adsorption tower, wherein a relationship among a size (short diameter) d of the bacterial cell, a pore size D1 of the adsorbent, and a minimum void size D2 between adsorbent particles, D1<d<D2 is satisfied; step (C) of bringing an eluent into contact with the adsorbent to elute the fermentation product; and step (D) of culturing the microorganism with a second culture medium using the collected effluent containing the bacterial cells and the raw materials for culture.

Materials and methods for generating protein-polymer conjugates on solid supports are provided herein. The methods can include, for example, reversibly immobilizing a protein on a solid support, modifying the protein by adding polymer subunits, and releasing the protein-polymer conjugate from the solid support.

The present invention provides a polypeptide having protease activity for use in the treatment or prevention of coronavirus infection in a mammal. In particular, the invention relates to treatment or prevention of a coronavirus infection in a human, using trypsins.

Compositions and methods for treating or preventing S. aureus infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce S. aureus populations and thereby treat or prevent infection by S. aureus. The compositions include one or more digestive enzymes, for example, one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.

Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule.

Compositions and methods for treating or preventing S. aureus infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce S. aureus populations and thereby treat or prevent infection by S. aureus. The compositions include one or more digestive enzymes, e.g., one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.

A therapeutic composition for the treatment of the symptoms of Williams Syndrome and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of Williams Syndrome, or the likelihood of an individual to develop Williams Syndrome is disclosed.

Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule.

Embodiments of the invention provide at least one polymer covalently conjugated to an esterase. The at least one polymer includes a plurality of oxime functional groups.

Embodiments of the invention provide at least one polymer covalently conjugated to an esterase. The at least one polymer includes a plurality of oxime functional groups.